0001628280-24-027720.txt : 20240611 0001628280-24-027720.hdr.sgml : 20240611 20240611182628 ACCESSION NUMBER: 0001628280-24-027720 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240607 FILED AS OF DATE: 20240611 DATE AS OF CHANGE: 20240611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stein Jeffrey CENTRAL INDEX KEY: 0001478831 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 241037043 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE, SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 4 1 wk-form4_1718144781.xml FORM 4 X0508 4 2024-06-07 0 0001610618 Cidara Therapeutics, Inc. CDTX 0001478831 Stein Jeffrey 6310 NANCY RIDGE DRIVE, STE 101 SAN DIEGO CA 92121 1 1 0 0 President & CEO 0 Common Stock 2024-06-07 4 P 0 8000 13.21 A 24580 I By trust Common Stock 57884 D Common Stock 2100 I By son The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.05 to $13.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Includes 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2024. /s/ Shane Ward, Attorney-in-Fact 2024-06-11